纳武利尤单抗联合化疗对比安慰剂联合化疗一线治疗HER2阴性、不可切除晚期或复发性胃癌或胃食管结合部癌(ATTRACTION-4):一项随机、多中心、双盲、安慰剂对照3期试验
ATTRACTION-4研究在日韩台130个中心随机入组724例HER2阴性、不可切除晚期或复发性胃癌或胃食管结合部癌患者,比较纳武利尤单抗联合奥沙利铂类化疗与安慰剂联合化疗。预设中期分析中位无进展生存期分别为10.45个月和8.34个月(HR 0.68,98.51% CI 0.51-0.90,p=0.0007),最终分析中位总生存期分别为17.45个月和17.15个月(HR 0.90,95% CI 0.75-1.08,p=0.26),未达统计学显著。
要点
- 纳武利尤单抗联合化疗较安慰剂联合化疗显著改善无进展生存期(HR 0.68,98.51% CI 0.51-0.90)。
- 最终分析中两组总生存期无显著差异(HR 0.90,95% CI 0.75-1.08,p=0.26)。
- 纳武利尤单抗组治疗相关严重不良事件发生率25%,高于安慰剂组的14%。
核心结论
- 在亚洲HER2阴性、未经治疗、不可切除晚期或复发性胃癌或胃食管结合部癌患者中,纳武利尤单抗联合奥沙利铂类化疗显著改善无进展生存期,但未显著改善总生存期,作者认为其可能成为这些患者的新一线治疗选择。
研究设计与样本
- 随机、多中心、双盲、安慰剂对照的2-3期试验(ATTRACTION-4),在横跨日本、韩国和台湾的130个中心(医院、癌症中心和医疗中心)进行。
- 入组724例患者,按1:1随机分配至纳武利尤单抗联合化疗组(362例)或安慰剂联合化疗组(362例)。
- 主要终点为意向治疗人群中经中心评估的无进展生存期和总生存期,安全性在所有至少接受一剂研究治疗的患者中评估。
主要发现
- 预设中期分析(数据截止2018年10月31日,中位随访11.6个月)中位无进展生存期:纳武利尤单抗联合化疗组10.45个月(95% CI 8.44-14.75) vs 安慰剂联合化疗组8.34个月(95% CI 6.97-9.40),HR 0.68(98.51% CI 0.51-0.90),p=0.0007。
- 最终分析(数据截止2020年1月31日,中位随访26.6个月)中位总生存期:纳武利尤单抗联合化疗组17.45个月(95% CI 15.67-20.83) vs 安慰剂联合化疗组17.15个月(95% CI 15.18-19.65),HR 0.90(95% CI 0.75-1.08),p=0.26。
- 最常见的治疗相关3-4级不良事件为中性粒细胞计数降低:纳武利尤单抗联合化疗组71/359例(20%) vs 安慰剂联合化疗组57/358例(16%);血小板计数降低:34/359例(9%) vs 33/358例(9%)。
- 治疗相关任何级别严重不良事件:纳武利尤单抗联合化疗组88/359例(25%) vs 安慰剂联合化疗组51/358例(14%),最常见为食欲下降:18/359例(5%) vs 10/358例(3%)。
- 治疗相关死亡共6例:纳武利尤单抗联合化疗组3例(发热性中性粒细胞减少症、肝衰竭、猝死各1例),安慰剂联合化疗组3例(脓毒症、溶血性贫血、间质性肺病各1例)。
临床怎么用
- 作者认为,纳武利尤单抗联合奥沙利铂类化疗可能成为亚洲HER2阴性、未经治疗、不可切除晚期或复发性胃癌或胃食管结合部癌患者的新一线治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The additive or synergistic sustained antitumour effect of immune checkpoint inhibitors in combination with oxaliplatin-based chemotherapy has previously been reported. We investigated the efficacy of nivolumab plus oxaliplatin-based chemotherapy versus placebo plus oxaliplatin-based chemotherapy as first-line therapy for patients with HER2-negative, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer. METHODS: We did a randomised, multicentre, double-blind, placebo-controlled, phase 2-3 trial (ATTRACTION-4) at 130 centres (hospitals, cancer centres, and medical centres) across Japan, South Korea, and Taiwan. We enrolled patients aged 20 years and older with previously untreated (except for neoadjuvant or adjuvant chemotherapy completed ≥180 days before recurrence), HER2-negative, unresectable, advanced or recurrent gastric or gastro-oesophageal junction cancer (regardless of PD-L1 expression), at least one measurable lesion per Response Evaluation Criteria in Solid Tumours guidelines (version 1.1), and a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Patients were randomly assigned (1:1) to chemotherapy every 3 weeks (intravenous oxaliplatin 130 mg/m2 on day 1 plus either oral S-1 40 mg/m2 [SOX] or oral capecitabine 1000 mg/m2 [CAPOX], twice daily on days 1-14), in addition to either 360 mg nivolumab intravenously every 3 weeks (nivolumab plus chemotherapy group) or placebo (placebo plus chemotherapy group). Randomisation was done using an interactive web response system with block sizes of four and stratified by intensity of PD-L1 expression, ECOG performance status score, disease status, and geographical region. Patients, investigators, and the study sponsor were masked to treatment assignment. The primary endpoints were centrally assessed progression-free survival and overall survival in the intention-to-treat population, which included all randomly assigned patients. Safety was assessed in all patients who received at least one dose of the assigned treatment. This trial is registered with ClinicalTrials.gov, NCT02746796. Trial recruitment is complete and follow-up is ongoing. FINDINGS: Between March 23, 2017, and May 10, 2018, 724 patients were randomly assigned to treatment: 362 patients to the nivolumab plus chemotherapy group and 362 to the placebo plus chemotherapy group. At the time of data cutoff on Oct 31, 2018, with a median follow-up of 11·6 months (IQR 8·7-14·1), median progression-free survival at a prespecified interim analysis was 10·45 months (95% CI 8·44-14·75) in the nivolumab plus chemotherapy group and 8·34 months (6·97-9·40) in the placebo plus chemotherapy group (hazard ratio [HR] 0·68; 98·51% CI 0·51-0·90; p=0·0007). At the time of data cutoff on Jan 31, 2020, with a median follow-up of 26·6 months (IQR 24·1-29·0), median overall survival at the final analysis was 17·45 months (95% CI 15·67-20·83) in the nivolumab plus chemotherapy group and 17·15 months (15·18-19·65) in the placebo plus chemotherapy group (HR 0·90; 95% CI 0·75-1·08; p=0·26). The most common treatment-related grade 3-4 adverse events were neutrophil count decreased (71 [20%] of 359 patients in the nivolumab plus chemotherapy group vs 57 [16%] of 358 patients in the placebo plus chemotherapy group) and platelet count decreased (34 [9%] vs 33 [9%]). Treatment-related serious adverse events of any grade were observed in 88 (25%) patients in the nivolumab plus chemotherapy group and in 51 (14%) in the placebo plus chemotherapy group, of which the most common was decreased appetite (18 [5%] vs ten [3%]). Six treatment-related deaths occurred: three in the nivolumab plus chemotherapy group (one each of febrile neutropenia, hepatic failure, and sudden death) and three in the placebo plus chemotherapy group (one each of sepsis, haemolytic anaemia, and interstitial lung disease). INTERPRETATION: Nivolumab combined with oxaliplatin-based chemotherapy significantly improved progression-free survival, but not overall survival, in Asian patients with untreated, HER2-negative, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer, and could potentially be a new first-line treatment option for these patients. FUNDING: Ono Pharmaceutical and Bristol-Myers Squibb.
引用
- Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022. PMID: 35030335. doi:10.1016/S1470-2045(21)00692-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。